Company intelligence / Profile preview

On Target Pharma

West Lafayette, Indiana, United Statesontargetpharma.com ↗

Ownership: Private
Development stage: Other

Overview

On Target Laboratories develops targeted intraoperative molecular imaging agents that help surgeons visualize and remove more cancer during surgery. Their lead product, CYTALUX (pafolacianine), targets folate receptor alpha and has been approved for use in ovarian and lung cancer surgeries. The company’s technology originated from research at Purdue University led by Dr. Philip Low. Recent funding supports commercialization efforts.

Therapeutic areas: Oncology
Modalities: Small moleculeDiagnostic agent
Industry: Medical Imaging

Beyond the preview

Go deeper on On Target Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on On Target Pharma.

Explore the full profile